Sydney, Australia 15 April 2021 – Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that the first patient has been treated in the Phase II DISCO trial (Diagnostic Imaging Study of Copper-64 SARTATE™ Using PET on Patients With Known or Suspected Neuroendocrine Tumors). The DISCO…
Sydney, Australia 16 February 2021 – Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has successfully completed the assignment of its key patent portfolio from the University of Melbourne. The assignment from the University of Melbourne to Clarity provides Clarity with the full…
Sydney, Australia 15 December 2020 – Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has completed a capital raising of $25,000,410. Dr Alan Taylor, Executive Chairman of Clarity Pharmaceuticals, commented, “It has been a pivotal year for Clarity with numerous critical milestones achieved…
Sydney, Australia 3 November 2020 – Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that treatment has commenced in a 64/67Cu-SARTATETM theranostic trial of paediatric patients with neuroblastoma at Memorial Sloan Kettering Cancer Center (MSK) in New York City. The first patient was treated with…
NOTICE OF 2020 ANNUAL GENERAL MEETING Notice is hereby given that the Annual General Meeting of Shareholders of Clarity Pharmaceuticals Ltd will be held at 10:00am on Thursday 19th of November 2020 by webcast to transact the business set out below. The webcast will be hosted on Zoom – https://www.zoom.us/join. Meeting ID is: 998 5420…
Sydney, Australia 9 September 2020 – Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Rare Paediatric Disease Designation (RPDD) to 64Cu-SARTATE™, a diagnostic for the clinical management of neuroblastoma. Dr Alan Taylor, Clarity’s Executive Chairman, commented,…
Sydney, Australia 28 July 2020 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that the first patient has been treated in the C-BOBCAT study (Copper-64 BOmbesin in Breast CAncer Trial). The C-BOBCAT trial is a first-in-human, investigator-led clinical trial investigating 64Cu-SAR-Bombesin (SAR-BBN) in patients with hormone…
Sydney, Australia 23 July 2020 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has opened its trial of 67Cu-SARTATE™ for paediatric patients with neuroblastoma at Memorial Sloan Kettering Cancer Center (MSK) in New York City and recruitment has commenced. “We are very excited to…
Sydney, Australia and Los Angeles, California 21 July 2020 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, and ImaginAb, Inc., a company that harnesses the specificity of monoclonal antibodies, have entered into a collaboration agreement to develop new targeted theranostic (diagnostic and therapy) products for a broad range of cancer…
Sydney, Australia 3 June 2020 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to 67Cu-SARTATE™, a therapy for the clinical management of neuroblastoma. The FDA defines a “rare pediatric disease” (RPD)…